Published in Health Business Week, June 11th, 2004
AMDL's product revenues for the 3 months ended March 31, 2004, totaled $124,503, an 88.5% increase compared to product revenues of $66,036 for the 3 months ended March 31, 2003.
Net loss for the 3 months ended March 31, 2004, was $564,256 or ($0.03) per share compared to a net loss of $571,033, or ($0.06) per share, for the 3 months ended March 31, 2003.
"The company's primary objective remains receiving U.S. Food and Drug Administration clearance to market its...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.